Remove 2023 Remove HIV Treatment and Prevention Agents Remove Immunity
article thumbnail

Gilead hit with FDA clinical hold for batch of HIV trials

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV treatment candidates, though the rest of the drugmaker’s diverse pipeline remains unaffected. Gilead is considered the leading big pharma in HIV treatments. Shares in Nasdaq-listed Gilead opened 0.3%

article thumbnail

ADA 2025: Advances in Type 2 Diabetes Management With Tirzepatide

Pharmacy Times

The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target." He was joined by Laura, a patient who began tirzepatide treatment shortly after being diagnosed with T2D.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Pharmacy Times

Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents. Utilizing colony-stimulating factors (CSFs) decreases the incidence of severe FN.

article thumbnail

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

3 Although meloxicam injection delivers a non-opioid alternative for pain control, it is not recommended as a first-line agent when rapid onset of analgesia is needed due to its delayed onset. 2 REFERENCES 1. Meloxicam: Selective COX-2 inhibition in clinical practice. Seminars in Arthritis and Rheumatism. December 21, 2004. Subscribe Now!

article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. ARO-AAT and ARO-APOC3 are among the highest-phase products developing under Arrowhead’s pipeline for the treatment of liver diseases. R&D Expenditure: $85.1M R&D Expenditure: $437.9M

article thumbnail

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Pharmacy Times

SHOW MORE Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis. Ongoing research explores tafamidis' long-term efficacy, potential in other heart failure forms, and combination therapies for enhanced outcomes.

article thumbnail

How Balancing Iron Levels Can Help Your Thyroid

The Thyroid Pharmacist

And as we’ve seen, even with supplementation, you need to address your root causes to prevent iron supply and demand challenges. Autoimmune Gastritis Autoimmune gastritis is a chronic inflammatory disease that occurs when your immune system attacks your stomach lining. Too much iron/ferritin can be a problem.